Disability

Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) at the 2025 PNS Meeting

First Oral Presentation by the International Guillain-Barré Syndrome Outcomes Study (IGOS) of the Real-World Evidence (RWE) Results Showing Improved Outcomes...

MIB acquires Clareto, forming strategic partnership with Munich Re Life US to expand access to electronic medical data and develop advanced data analytics

BRAINTREE, Mass. and NEW YORK, May 2, 2025 /PRNewswire/ -- MIB, the life insurance industry's most trusted and secure partner for...

Acentra Health Awarded $27.5 Million Contract from California Medicaid to Continue Providing Preadmission Screening and Resident Review (PASRR) Services

Award follows new contracts in Kansas and Washington and expands the company’s PASRR services for long-term care assessments to eight...

Acentra Health Awarded $27.5 Million Contract from California Medicaid to Continue Providing Preadmission Screening and Resident Review (PASRR) Services

Award follows new contracts in Kansas and Washington and expands the company’s PASRR services for long-term care assessments to eight...

Four-year Follow-up Data on SPRINT® PNS for Low Back Pain Highlights Sustained Pain Relief Avoiding Costly and Invasive Treatments

CLEVELAND, April 29, 2025 (GLOBE NEWSWIRE) -- SPR announced the publication of long-term follow-up survey data from a prospective, multicenter...

Four-year Follow-up Data on SPRINT® PNS for Low Back Pain Highlights Sustained Pain Relief Avoiding Costly and Invasive Treatments

CLEVELAND, April 29, 2025 (GLOBE NEWSWIRE) -- SPR announced the publication of long-term follow-up survey data from a prospective, multicenter...

Levicept Presents Positive Phase II Data for Novel Neurotrophin-3 Inhibitor, LEVI-04, at 2025 World Congress on Osteoarthritis

Plenary presentation of data showing primary efficacy endpoint met – significant analgesia across all dosesSignificant improvement in all signs and...

error: Content is protected !!